BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24645668)

  • 1. Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.
    Zhao X; Rødland EA; Sørlie T; Vollan HK; Russnes HG; Kristensen VN; Lingjærde OC; Børresen-Dale AL
    BMC Cancer; 2014 Mar; 14():211. PubMed ID: 24645668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
    Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
    Szekely B; Iwamoto T; Szasz AM; Qi Y; Matsuoka J; Symmans WF; Tokes AM; Kulka J; Swanton C; Pusztai L
    Breast Cancer Res Treat; 2013 Apr; 138(3):691-8. PubMed ID: 23504136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
    Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
    PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.
    Fan C; Prat A; Parker JS; Liu Y; Carey LA; Troester MA; Perou CM
    BMC Med Genomics; 2011 Jan; 4():3. PubMed ID: 21214954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
    Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
    Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
    Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
    BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
    Roylance R; Endesfelder D; Gorman P; Burrell RA; Sander J; Tomlinson I; Hanby AM; Speirs V; Richardson AL; Birkbak NJ; Eklund AC; Downward J; Kschischo M; Szallasi Z; Swanton C
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2183-94. PubMed ID: 21784954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
    Laas E; Mallon P; Duhoux FP; Hamidouche A; Rouzier R; Reyal F
    PLoS One; 2016; 11(2):e0148957. PubMed ID: 26895349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
    Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström LS; Tobin NP
    Breast Cancer Res; 2024 Mar; 26(1):38. PubMed ID: 38454481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.
    Vollan HK; Rueda OM; Chin SF; Curtis C; Turashvili G; Shah S; Lingjærde OC; Yuan Y; Ng CK; Dunning MJ; Dicks E; Provenzano E; Sammut S; McKinney S; Ellis IO; Pinder S; Purushotham A; Murphy LC; Kristensen VN; ; Brenton JD; Pharoah PD; Børresen-Dale AL; Aparicio S; Caldas C
    Mol Oncol; 2015 Jan; 9(1):115-27. PubMed ID: 25169931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic potential of alternative transcript isoforms across human tumors.
    Trincado JL; Sebestyén E; Pagés A; Eyras E
    Genome Med; 2016 Aug; 8(1):85. PubMed ID: 27535130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
    Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
    Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.